Sarcouncil Journal of Internal Medicine and Public Health

Abstract: Malignant lymphoma, encompassing both Hodgkin and non-Hodgkin subtypes, remains a significant health burden globally and in Iraq which Understanding the demographic, clinical, laboratory, and therapeutic factors influencing outcomes is essential for optimizing patient care and in this paper were prospective observational cohort study was conducted at an oncology referral center in Iraq from March 2023 to March 2025 with 100 newly diagnosed adult patients with histopathologic ally confirmed malignant lymphoma were enrolled which Data were collected on demographics, clinical presentation, laboratory findings, diagnostic modalities, treatment regimens, outcomes, patient satisfaction, and quality of life (SF-36). Logistic regression and Chi-square tests were used to identify risk factors and associations between variables, with statistical significance set at p<0.05. Of the 100 patients(50% were over 40 years old and 55% were male), Non-Hodgkin lymphoma was the predominant subtype (80%), with 45% presenting at advanced stages (III–IV) furthermore Chemotherapy was the main treatment (70%), followed by radiation (30%), immunotherapy (20%), and stem cell transplantation (10%) with 60 of patients successfully completed treatment, while 40% achieved complete response in addition to Patient satisfaction was high (80% satisfied or very satisfied), though 20% were dissatisfied. Quality of life scores were moderate, with social function and general health domains scoring highest with Logistic regression identified older age, male gender, low socioeconomic status, and smoking as significant risk factors for adverse outcomes also were Statistically significant associations were observed between age and treatment response (p=0.022), gender and satisfaction (p=0.033), and socioeconomic status and treatment outcome (p=0.014) so finally. This study highlights the predominance of non-Hodgkin lymphoma, the central role of chemotherapy, and the impact of demographic and socioeconomic factors on treatment outcomes and quality of life among Iraqi patients.